

# Ontario Drug Benefit Formulary/Comparative Drug Index

Edition 43

Summary of Changes – October 2019

Effective October 31, 2019

Drug Programs Policy and Strategy Branch  
Drugs and Devices Division  
Ministry of Health

[Visit Formulary Downloads: Edition 43](#)

# Table of Contents

New Single Source Products.....	3
New Multi-Source Products.....	4
New Off-Formulary Interchangeable (OFI) Products.....	6
Addition of Reason For Use Code.....	7
Transition from Exceptional Access Program to General Benefit.....	8
Product Brand Name Change .....	9
Product Brand and Manufacturer Name Changes .....	10
Drug Benefit Price (DBP) Changes .....	11
Discontinued Products .....	14
Delisted Products.....	15

# New Single Source Products

DIN/PIN	Brand Name	Strength	Dosage Form	Generic Name	Mfr	DBP
02482592	Delstrigo	100mg & 300mg & 300mg	Tab	DORAVIRINE/LAMIVU DINE/TENOFOVIR DISOPROXIL FUMARATE	MEK	28.7900

## Therapeutic Notes:

As a complete regimen for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to DOR, 3TC, or tenofovir.

For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.

DIN/PIN	Brand Name	Strength	Dosage Form	Generic Name	Mfr	DBP
02481545	Pifeltro	100mg	Tab	DORAVIRINE	MEK	16.6500

## Therapeutic Notes:

In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to DOR.

For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.

# New Multi-Source Products

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02483734	Jamp-Clindamycin	150mg	Cap	JPC	0.2217
02483742	Jamp-Clindamycin	300mg	Cap	JPC	0.4434

(Interchangeable with Dalacin C)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02487012	Jamp- Emtricitabine/Tenofovir Disoproxil Fumarate	200mg & 300mg	Tab	JPC	7.3035

(Interchangeable with Truvada)

Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.

For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.

For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada's approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.

## New Multi-Source Products (Continued)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02489406	Riva-Labetalol	100mg	Tab	RIA	0.2974
02489414	Riva-Labetalol	200mg	Tab	RIA	0.5256

(Interchangeable with Trandate)

# New Off-Formulary Interchangeable (OFI) Products

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02468891	Apo-Dabigatran	75mg	Cap	APX	1.4552

(Interchangeable with Pradaxa)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02482525	Jamp-Zoledronic Acid	4mg/5mL	Inj Sol-5mL Pk (Preservative Free)	JPC	415.5600

(Interchangeable with Zometa Concentrate)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02491796	Nat-Gefitinib	250mg	Tab	NAT	62.3050

(Interchangeable with Iressa)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02469782	PMS-Fingolimod	0.5mg	Cap	PMS	73.9096

(Interchangeable with Gilenya)

# Addition of Reason For Use Code

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr
02408163	Fibristal	5mg	Tab	ALL

## Reason For Use Code and Clinical Criteria

### Code 566

For the pre-operative treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, and the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are not eligible for surgery with the duration of each treatment course being three months, if the following conditions are met:

- The maximum supply is limited to a total of four courses of therapy per patient per lifetime.
- The patient is under the care of a physician experienced in the management of gynecological conditions such as uterine fibroids.

LU Authorization Period: Maximum 4 courses of therapy

# Transition from Exceptional Access Program to General Benefit

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP
02240329	One-Alpha Drops	2mcg/mL	Oral Drops	LEO	6.2580



# Product Brand Name Change

DIN/PIN	Current Brand Name	New Brand Name	Strength	Dosage Form	Mfr
02411008*	Gabapentin Tablets USP	GLN-Gabapentin	800mg	Tab	GLP

\*Off Formulary Interchangeable

# Product Brand and Manufacturer Name Changes

DIN/PIN	Current Brand Name	Current Mfr	New Brand Name	New Mfr	Strength	Dosage Form
00445274	Apo-Sulfatrim	APX	Sulfatrim	AAP	400mg & 80mg	Tab
00445282	Apo-Sulfatrim-DS	APX	Sulfatrim-DS	AAP	800mg & 160mg	Tab
02309556*	Novo-Cyproterone/Ethinyl Estradiol	NOP	Teva-Cyproterone/Ethinyl Estradiol	TEV	2mg & 0.035mg	Tab-21Pk

\*Off Formulary Interchangeable

# Drug Benefit Price (DBP) Changes

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr	DBP/ Unit Price
00522724	Chlordiazepoxide	5mg	Cap	AAP	0.0725
00522996	Chlordiazepoxide	25mg	Cap	AAP	0.1740
02453908	Act- Buprenorphine/Naloxone	2mg & 0.5mg	SL Tab	ACV	1.3350
02453916	Act Buprenorphine/Naloxone	8mg & 2mg	SL Tab	ACV	2.3650
02299615	Apo-Dorzo-Timop	2% & 0.5%	Oph Sol	APX	2.0951
02279215	Apo-Raloxifene	60mg	Tab	APX	0.4701
02261642	PMS-Azithromycin	600mg	Tab	PMS	10.6652
02424851	PMS-Buprenorphine- Naloxone	2mg & 0.5mg	SL Tab	PMS	1.3350
02424878	PMS-Buprenorphine- Naloxone	8mg & 2mg	SL Tab	PMS	2.3650
02455331	Brenzys	50mg/mL	Sol-Pref AutoInj	SAM	241.0000
02455323	Brenzys	50mg/mL	Inj Sol-Pref Syr	SAM	241.0000
00800430	Vancocin	125mg	Cap	SLP	5.3485

## Discontinued Products

(Some products will remain on Formulary for six months to facilitate depletion of supply)

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr
02049996	Doxepin	10mg	Cap	AAP
02050005	Doxepin	25mg	Cap	AAP
02050013	Doxepin	50mg	Cap	AAP
02050021	Doxepin	75mg	Cap	AAP
02050048	Doxepin	100mg	Cap	AAP
02295377*	Apo-Glimepiride	1mg	Tab	APX
02295385*	Apo-Glimepiride	2mg	Tab	APX
02295393*	Apo-Glimepiride	4mg	Tab	APX
02291983	Gd-Celecoxib	200mg	Cap	GEM
02285843*	Gd-Gabapentin	600mg	Tab	GEM
02205963**	Dexiron	50mg/mL	Inj-2mL Pk	LUI
02309254	Niaspan FCT	500mg	ER Tab	SUO
02309289	Niaspan FCT	1000mg	ER Tab	SUO

\*Off Formulary Interchangeable

\*\* Exceptional Access Program

# Delisted Products

DIN/PIN	Brand Name	Strength	Dosage Form	Mfr
02367866	Apo-Candesartan/HCTZ	16mg & 12.5mg	Tab	APX
02395126	Apo-Candesartan/HCTZ	32mg & 12.5mg	Tab	APX
02395134	Apo-Candesartan/HCTZ	32mg & 25mg	Tab	APX
02096900*	Enemol	160mg & 60mg/mL	Rect Sol (with Preservative)	DPC
02408090	Mylan-Buprenorphine/Naloxone	2mg & 0.5mg	SL Tab	MYL
02408104	Mylan-Buprenorphine/Naloxone	8mg & 2mg	SL Tab	MYL
00761656**	Rhotrimine	75mg	Cap	SAV
00761648**	Rhotrimine	100mg	Cap	SAV

\*Pharmacists are encouraged to plan accordingly and to transition patients as necessary to ensure continuity in drug therapy for their patients, as well as counsel affected patients appropriately

\*\*Not-a-Benefit

